Morgan Stanley cuts India’s FY27 growth outlook to 6.2% amid Gulf conflict

The pharma sector, while often seen as defensive, faces margin compression from increased input costs due to global supply chain disruptions. This could temper growth expectations despite underlying demand.

Monitor pharma and textile stocks for signs of increased input costs impacting quarterly results; consider shorting or reducing positions in companies with high import dependencies.

For Indian markets, this story mainly matters for , and the Pharmaceuticals, Textiles, Economy pocket. The current signal is bearish, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: Face margin pressures due to rising costs linked to the Gulf conflict. Face margin pressures due to rising costs linked to the Gulf conflict. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Morgan Stanley cut India's FY27 growth forecast to 6.2%.
• •The adjustment is due to supply disruptions and rising costs from the Gulf conflict.
• •Inflation is now projected to reach 5.1%.
• •The current account deficit may widen to 2.5% of GDP.
• •Pharmaceuticals and textiles sectors are expected to face margin pressures.